Researchers mimic mussels for delivery 'glue'; HGH nasal spray passes second clinical trial;

> Researchers at Northwestern University are using a material based on the glue that holds mussels to rocks underwater to help during surgical repair and polymer-based drug delivery. Release

> Critical Pharmaceuticals completed a second clinical study of its CP024 human growth hormone nasal spray, an alternative to injections for children and adults with growth disorders. Release

> New Jersey-based mPhase Technologies filed a patent application for a novel drug delivery system based on its Smart Surface technology, which enables the precise control of a fluid on a nano-structured surface. Release

> Mylan ($MYL) entered into an agreement with Biocon for the global development and commercialization of Biocon's insulin analog products with a potential market of $11.5 billion. Biocon is also in the market with Bristol-Myers Squibb ($BMY) and the company's pursuit of oral insulin approval. Story

> Gamida Cell saw successful results in its Phase I/II study of NiCord, stem cells derived from the umbilical cord that are designed to treat patients with high-risk blood disorders. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.